# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women

> **NCT01224717** · PHASE1 · COMPLETED · sponsor: **Novartis** · enrollment: 104 (actual)

## Conditions studied

- Post-menopausal Osteoporosis

## Interventions

- **DRUG:** PTH134
- **DRUG:** Placebo
- **DRUG:** Forsteo

## Key facts

- **NCT ID:** NCT01224717
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2011-04
- **Final completion:** —
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2011-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01224717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01224717, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01224717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*